score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.K3313T	0.4159	113.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA2 p.K3313T (Missense)	0.0	KIRP-B1-A654	KIRP-B1-A654-TP	KIRP-B1-A654-NB
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Frameshift	p.K596fs	0.4429	70.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	0.0	0.0	0.0	BARD1 p.K596fs (Frameshift)	0.0	KIRP-B1-A654	KIRP-B1-A654-TP	KIRP-B1-A654-NB
Biologically Relevant				Somatic Variant	POT1	Missense	p.K171E	0.2848	158.0	0.0	0.0																					0	0.0	0.0	0.0	POT1 p.K171E (Missense)		KIRP-B1-A654	KIRP-B1-A654-TP	KIRP-B1-A654-NB
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.APP65del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.APP65del (Deletion)		KIRP-B1-A654		
Biologically Relevant				Mutational Signature	COSMIC Signature 14	version 2	0.22																									0				COSMIC Signature (version 2) 14 (22%)		KIRP-B1-A654		
Biologically Relevant				Mutational Signature	COSMIC Signature 20	version 2	0.3																									0				COSMIC Signature (version 2) 20 (30%)		KIRP-B1-A654		
